MD
NEUTRAL
$22.31
Live
Pediatrix Medical Group, Inc. · NYSE
Target $22.17
(-0.6%)
$11.84
52W Range
$24.99
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 30, 2026
Market cap
$1.85B
P/E
11.5
ROE
20.3%
Profit margin
8.6%
Debt/Equity
0.73
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
80%
Pediatrix Medical Group (MD) presents a complex profile with a Piotroski F-Score of 4/9, indicating stable but mediocre financial health. While the company is significantly undervalued on a relative basis (P/E 11.50 vs Sector 73.97) and shows a highly attractive PEG ratio of 0.24, these fundamentals are countered by negative revenue growth (-1.70%) and bearish insider activity. The stock is currently trading near its Graham Number ($21.60), suggesting it is fairly valued from a defensive standpoint, despite a much higher growth-based intrinsic value of $46.75.
Key Strengths
Extremely low P/E and Forward P/E relative to healthcare sector averages
Strong Return on Equity (ROE) of 20.28%
Attractive PEG ratio (0.24) suggesting significant undervaluation relative to earnings growth
Manageable Debt/Equity ratio (0.73) compared to sector average (2.64)
Strong 1-year price recovery (+77.6%)
Key Risks
Negative year-over-year and quarter-over-quarter revenue growth
Bearish insider sentiment with CEO and Directors selling shares
Low Piotroski F-Score (4/9) indicating lack of strong financial momentum
Bearish technical trend (10/100) despite recent price gains
Recent Q/Q EPS growth decline of -25.4%
AI Fair Value Estimate
Based on comprehensive analysis
$34.18
+53.2% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
48
Moderate
90
40
60
50
0
AI Verdict
Value Trap Risk
Key drivers: Deep valuation discount, Stagnant revenue growth, Insider selling, Stable but not strong balance sheet
Confidence
85%
Value
90/100
Ref P/E, PEG, Graham Number
Positives
- P/E of 11.50 is very low
- PEG of 0.24 is exceptional
- Price/Sales under 1.0
Watchpoints
- Trading slightly above Graham Number
Future
40/100
Ref Growth rates
Positives
- Positive YoY earnings growth (11.4%)
Watchpoints
- Negative revenue growth (-1.7%)
- Recent Q/Q EPS drop
Past
60/100
Ref Historical trends
Positives
- Strong 1Y and 6M price performance
- Consistent history of earnings beats
Watchpoints
- Negative 5Y total return
Health
50/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio 1.66 indicates good liquidity
- Debt/Equity is well below sector average
Watchpoints
- Piotroski F-Score of 4/9 is only 'Stable'
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend payments
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$22.31
Analyst Target
$22.17
Upside/Downside
-0.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for MD and closest competitors.
Updated 2026-04-29
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
MD
Pediatrix Medical Group, Inc.
Primary
|
-15.2% | +55.7% | +77.6% | +24.9% | +7.3% | -2.4% |
|
ANAB
AnaptysBio, Inc.
Peer
|
+227.2% | +183.1% | +284.9% | +177.0% | +17.3% | +17.0% |
|
AZTA
Azenta, Inc.
Peer
|
-50.6% | -29.6% | -26.9% | +16.3% | +16.1% | +0.1% |
|
GRAL
GRAIL, Inc.
Peer
|
+234.0% | +234.0% | +100.6% | -31.0% | -1.5% | -17.0% |
|
ADUS
Addus HomeCare Corporation
Peer
|
-6.0% | +1.0% | +11.6% | -8.1% | -10.1% | -1.8% |
MD
Pediatrix Medical Group, Inc.
Primary
5Y
-15.2%
3Y
+55.7%
1Y
+77.6%
6M
+24.9%
1M
+7.3%
1W
-2.4%
ANA
AnaptysBio, Inc.
Peer
5Y
+227.2%
3Y
+183.1%
1Y
+284.9%
6M
+177.0%
1M
+17.3%
1W
+17.0%
AZT
Azenta, Inc.
Peer
5Y
-50.6%
3Y
-29.6%
1Y
-26.9%
6M
+16.3%
1M
+16.1%
1W
+0.1%
GRA
GRAIL, Inc.
Peer
5Y
+234.0%
3Y
+234.0%
1Y
+100.6%
6M
-31.0%
1M
-1.5%
1W
-17.0%
ADU
Addus HomeCare Corporation
Peer
5Y
-6.0%
3Y
+1.0%
1Y
+11.6%
6M
-8.1%
1M
-10.1%
1W
-1.8%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
11.5
Forward P/E
9.59
PEG Ratio
0.24
P/B Ratio
2.09
P/S Ratio
0.97
EV/Revenue
1.01
EV/EBITDA
7.68
Market Cap
$1.85B
Profitability
Profit margins and return metrics
Profit Margin
8.64%
Operating Margin
11.07%
Gross Margin
25.8%
ROE
20.28%
ROA
6.57%
Growth
Revenue and earnings growth rates
Revenue Growth
-1.7%
Earnings Growth
+11.4%
Q/Q Revenue Growth
-1.71%
Q/Q Earnings Growth
+10.5%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.73
Moderate
Current Ratio
1.66
Good
Quick Ratio
1.62
Excellent
Cash/Share
$6.16
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.5B
Gross Margin
25.5%
Op. Margin
11.1%
Net Margin
6.8%
Total Assets
$2.2B
Liabilities
$1.4B
Equity
$0.9B
Debt/Equity
1.59x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.1B
FCF Yield
95%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-05
$N/A
2026-02-19
$0.5
-7.1% surprise
2025-11-03
$0.67
+43.9% surprise
2025-08-05
$0.53
+24.9% surprise
Healthcare Sector Comparison
Comparing MD against 570 companies in the Healthcare sector
(37 bullish, 174 neutral, 359 bearish)
P/E Ratio
11.5
This Stock
vs
73.1
Sector Avg
-84.3%
(Discount)
Return on Equity (ROE)
20.28%
This Stock
vs
-86.81%
Sector Avg
-123.4%
(Below Avg)
Profit Margin
8.64%
This Stock
vs
-15.96%
Sector Avg
-154.2%
(Weaker)
Debt to Equity
0.73
This Stock
vs
2.63
Sector Avg
-72.1%
(Less Debt)
Revenue Growth
-1.7%
This Stock
vs
122.05%
Sector Avg
-101.4%
(Slower)
Current Ratio
1.66
This Stock
vs
4.44
Sector Avg
-62.5%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
MD
Pediatrix Medical Group, Inc.
|
NEUTRAL | $1.85B | 11.5 | 20.3% | 8.6% | $22.31 | |
|
ANAB
AnaptysBio, Inc.
|
BULLISH | $1.86B | - | -24.5% | -5.6% | $64.81 | Compare |
|
AZTA
Azenta, Inc.
|
NEUTRAL | $1.84B | 77.02 | 1.4% | -9.4% | $40.05 | Compare |
|
GRAL
GRAIL, Inc.
|
BEARISH | $1.87B | - | -16.1% | -277.5% | $45.63 | Compare |
|
ADUS
Addus HomeCare Corporation
|
NEUTRAL | $1.88B | 19.42 | 9.3% | 6.7% | $101.35 | Compare |
MD
Pediatrix...
NEUTRAL
Mkt Cap
$1.9B
P/E
11.5
ROE
20.3%
Price
$22.31
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-27 | MOORE MARY ANN E | General Counsel | Stock Award | 39,925 | - |
| 2025-12-15 | ORDAN MARK S | Chief Executive Officer | Sale | 23,000 | $515,430 |
| 2025-11-17 | RUCKER MICHAEL A | Director | Sale | 10,478 | $240,994 |
| 2025-11-06 | LINYNSKY LAURA A | Director | Sale | 10,000 | $216,500 |
MOORE MARY ANN E
General Counsel
2026-02-27
39,925 shares
ORDAN MARK S
Chief Executive Officer
2025-12-15
23,000 shares
·
$515,430
RUCKER MICHAEL A
Director
2025-11-17
10,478 shares
·
$240,994
LINYNSKY LAURA A
Director
2025-11-06
10,000 shares
·
$216,500
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
DEF 14A
10-K
10-Q
8-K
10-Q
8-K
8-K
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
6 analysts
Truist Securities
2026-04-13
Hold
Hold
UBS
2026-02-24
Neutral
Neutral
Truist Securities
2026-02-20
Hold
Hold
Truist Securities
2025-11-10
Hold
Hold
UBS
2025-11-05
Neutral
Neutral
Past News Coverage
Recent headlines mentioning MD from our newsroom.
Newest → oldest
No matching news yet.